Bristol-Myers Squibb Company (BMY) Net Profit Margin: 15.01%
Is Bristol-Myers Squibb Company’s net profit margin high or low?
Bristol-Myers Squibb Company's net profit margin of 15.01% is 318% above its 5-year average of 3.59%, near the high end of its 5-year range (-21.16%–17.83%).
The net profit margin for Bristol-Myers Squibb Company (BMY) is 15.01% as of Wednesday, June 10, 2026. It is above its 12-month average by 869.74% (-1.95%).
BMY Net Profit Margin Chart
BMY Average Net Profit Margin Chart
BMY Current vs Average Net Profit Margin Chart
BMY Net Profit Margin Metrics
NET PROFIT MARGIN
15.01%
NET PROFIT MARGIN AVG TTM
-1.95%
NET PROFIT MARGIN AVG 3Y
6.91%
NET PROFIT MARGIN AVG 5Y
3.59%
NET PROFIT MARGIN AVG 10Y
8.52%
NET PROFIT MARGIN AVG 15Y
10.41%
NET PROFIT MARGIN AVG 20Y
13.53%
CURRENT VS TTM AVG
+869.74%
CURRENT VS 3Y AVG
+117.22%
CURRENT VS 5Y AVG
+317.72%
CURRENT VS 10Y AVG
+76.10%
CURRENT VS 15Y AVG
+44.22%
CURRENT VS 20Y AVG
+10.96%
BMY Competitors' Net Profit Margin
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bristol-Myers Squibb Company (BMY) | $114.14B | 15.01% | -1.95% | 6.91% | 3.59% |
| Vertex Pharmaceuticals Incorporated (VRTX) | $110.77B | 35.40% | 13.94% | 25.44% | 29.40% |
| CVS Health Corporation (CVS) | $125.16B | 0.72% | 0.84% | 1.34% | 1.79% |
| Medtronic plc (MDT) | $103.04B | 13.20% | 13.55% | 12.62% | 13.06% |
| Danaher Corporation (DHR) | $130.25B | 14.89% | 15.52% | 19.51% | 19.37% |
| Elevance Health Inc. (ELV) | $87.43B | 2.62% | 3.11% | 3.37% | 3.60% |
| Pfizer Inc. (PFE) | $146.36B | 11.83% | 12.51% | 14.97% | 18.18% |
| Intuitive Surgical, Inc. (ISRG) | $146.44B | 28.15% | 28.09% | 25.67% | 26.14% |
| Cigna Corporation (CI) | $78.25B | 2.26% | 1.78% | 2.48% | 3.04% |
| Gilead Sciences, Inc. (GILD) | $151.21B | 30.99% | 15.29% | 17.07% | 15.27% |
Margin Comparison
Operating Margin
25.7%
Net Profit Margin
15.0%
Bristol-Myers Squibb Company Net Profit Margin Formula & Definition
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Bristol-Myers Squibb Company Net Profit Margin FAQ
- What is the net profit margin for Bristol-Myers Squibb Company (BMY)?
- The net profit margin for BMY stock is 15.01%.
- Is Bristol-Myers Squibb Company's net profit margin high or low?
- Bristol-Myers Squibb Company's net profit margin of 15.01% is 318% above its 5-year average of 3.59%, near the high end of its 5-year range (-21.16%–17.83%).
- What is the TTM average net profit margin for Bristol-Myers Squibb Company (BMY)?
- The TTM average net profit margin for BMY stock is -1.95%.
- What is the 3Y average net profit margin for Bristol-Myers Squibb Company (BMY)?
- The 3Y average net profit margin for BMY stock is 6.91%.
- What is the 5Y average net profit margin for Bristol-Myers Squibb Company (BMY)?
- The 5Y average net profit margin for BMY stock is 3.59%.
- What is the 10Y average net profit margin for Bristol-Myers Squibb Company (BMY)?
- The 10Y average net profit margin for BMY stock is 8.52%.
- What is the 15Y average net profit margin for Bristol-Myers Squibb Company (BMY)?
- The 15Y average net profit margin for BMY stock is 10.41%.
- What is the 20Y average net profit margin for Bristol-Myers Squibb Company (BMY)?
- The 20Y average net profit margin for BMY stock is 13.53%.
Bristol-Myers Squibb Company Net Profit Margin History
| DATE | NET PROFIT MARGIN |
|---|---|
| 2025-12-31 | 14.63% |
| 2024-12-31 | -18.53% |
| 2023-12-31 | 17.83% |
| 2022-12-31 | 13.71% |
| 2021-12-31 | 15.08% |
| 2020-12-31 | -21.16% |
| 2019-12-31 | 13.15% |
| 2018-12-31 | 21.81% |
| 2017-12-31 | 4.85% |
| 2016-12-31 | 22.94% |
| 2015-12-31 | 9.45% |
| 2014-12-31 | 12.62% |
| 2013-12-31 | 15.64% |
| 2012-12-31 | 11.12% |
| 2011-12-31 | 17.46% |
| 2010-12-31 | 15.92% |
| 2009-12-31 | 56.42% |
| 2008-12-31 | 25.47% |
| 2007-12-31 | 11.19% |
| 2006-12-31 | 8.85% |
| 2005-12-31 | 15.62% |
| 2004-12-31 | 12.32% |
| 2003-12-31 | 14.87% |
| 2002-12-31 | 11.79% |
| 2001-12-31 | 24.89% |
| 2000-12-31 | 25.86% |
| 1999-12-31 | 20.61% |
| 1998-12-31 | 17.18% |
| 1997-12-31 | 19.19% |
| 1996-12-31 | 18.92% |
Related Metrics
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Christopher S. Boerner